 |
|
|
| |
The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ± RBV in the Phase 3 ION Studies
|
| |
| |
Reported by Jules Levin
International Workshop on Antiviral Drug Resistance
June 3-6, 2014
Berlin, Germany
Hadas Dvory-Sobol1, Brian Doehle1, Evguenia Svarovskaia1, Joseph F. McCarville1, Phil S. Pang1, Nezam Afdhal2, Kris V. Kowdley3, John McHutchison1, Michael Miller1, and Hongmei Mo1
1Gilead Sciences, Inc., Foster City, CA, USA 2Beth Israel Deaconess Medical Center, Boston, MA, USA
3Digestive Disease Institute, Virginia Mason Medical Center, Seattle, USA
|
| |
|
|
|
|
|
